Alexion Acquires Swedish Treatment for Wilson's Disease
Alexion inks $855M takeover of Wilson Therapeutics | Fierce Biotech
ALXN1840 FoCus Phase III Trial in Wilson Disease Met Primary Endpoint Demonstrating Improvement in Copper Mobilisation from Tissues-CliniExpert
Wilson Disease - Neurologic Clinics
TETA4 Noninferior to Penicillamine for Stable Wilson's Disease | MedPage Today
Alexion Pharmaceuticals - Decades of low awareness and limited scientific research of Wilson disease, a rare and progressive genetic condition in which the body's pathway for removing excess copper is compromised, have
Wilson Disease - Practical Neurology
WTX101: A Superior Treatment for Wilson Disease
Alexion to Acquire Wilson Therapeutics for $855 Million - Equities News
Wilson disease | Nature Reviews Disease Primers
alxninvestorslides
Quality of Life in Wilson's Disease: A Systematic Literature Review | Published in Journal of Health Economics and Outcomes Research
Alexion buys Swedish biotech for $855M to broaden rare disease pipeline
Alexion bids $855m for rare disease biotech Wilson Therapeutics | pharmaphorum
Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver - The Lancet Gastroenterology & Hepatology
Alexion Acquires Swedish Treatment for Wilson's Disease
Wilson Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Veruska Sena posted on LinkedIn
THINK WILSON
alxninvestorslides
Alexion's drug meets primary goal in Phase III Wilson disease trial
Wilson disease. - Abstract - Europe PMC
